Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 94.5% in December

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 7,780,000 shares, a growth of 94.5% from the December 15th total of 4,000,000 shares. Approximately 4.2% of the company’s shares are short sold. Based on an average daily volume of 100,730,000 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Thursday, January 9th. They set a “hold” rating for the company.

Tonix Pharmaceuticals Trading Up 0.7 %

Shares of TNXP traded up $0.00 on Thursday, reaching $0.23. 55,722,110 shares of the company’s stock were exchanged, compared to its average volume of 66,936,844. The business has a 50 day moving average price of $0.26 and a two-hundred day moving average price of $0.31. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $12.48. The stock has a market capitalization of $43.73 million, a P/E ratio of 0.00 and a beta of 2.02. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Research analysts anticipate that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.